A293780 Stock Overview
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AptaBio Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,590.00 |
| 52 Week High | ₩15,490.00 |
| 52 Week Low | ₩4,930.00 |
| Beta | 1.96 |
| 11 Month Change | -19.63% |
| 3 Month Change | -20.02% |
| 1 Year Change | -18.14% |
| 33 Year Change | -81.82% |
| 5 Year Change | -29.71% |
| Change since IPO | -66.12% |
Recent News & Updates
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 29
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Recent updates
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 29Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?
Feb 23Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01
Shareholder Returns
| A293780 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.9% | -3.5% | 2.5% |
| 1Y | -18.1% | 24.9% | -1.1% |
Return vs Industry: A293780 underperformed the KR Biotechs industry which returned 18.1% over the past year.
Return vs Market: A293780 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A293780 volatility | |
|---|---|
| A293780 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A293780's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A293780's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Jin Soo | www.aptabio.com |
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH).
AptaBio Therapeutics Inc. Fundamentals Summary
| A293780 fundamental statistics | |
|---|---|
| Market cap | ₩177.15b |
| Earnings (TTM) | -₩20.10b |
| Revenue (TTM) | ₩2.91b |
61.0x
P/S Ratio-8.8x
P/E RatioIs A293780 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A293780 income statement (TTM) | |
|---|---|
| Revenue | ₩2.91b |
| Cost of Revenue | ₩2.68b |
| Gross Profit | ₩226.00m |
| Other Expenses | ₩20.33b |
| Earnings | -₩20.10b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -747.82 |
| Gross Margin | 7.78% |
| Net Profit Margin | -691.71% |
| Debt/Equity Ratio | 27.3% |
How did A293780 perform over the long term?
See historical performance and comparison